LivaNova (NASDAQ:LIVN – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17, FiscalAI reports. The company had revenue of $390.59 million for the quarter, compared to the consensus estimate of $380.50 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. LivaNova’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.05 EPS. LivaNova updated its FY 2026 guidance to 4.300-4.400 EPS.
Here are the key takeaways from LivaNova’s conference call:
- Q2 revenue rose 9.8% on a constant-currency basis to a record $391 million, while adjusted EPS increased to $1.26 from $1.05, supported by growth in Cardiopulmonary and Epilepsy.
- LivaNova raised its 2026 revenue-growth outlook to 8%–9% and adjusted EPS guidance to $4.30–$4.40; Cardiopulmonary and Epilepsy growth expectations were also increased.
- The company is expanding oxygenator capacity through a new production line expected to go live in the second half of 2026 and a long-term Thermo Fisher agreement for a critical component, supporting potential market-share gains.
- Epilepsy momentum benefited from improved reimbursement, clinical evidence, higher realized pricing and a stronger patient funnel; management said new-patient implants are growing in existing accounts and through new account activations.
- Adjusted free-cash-flow guidance was reduced to $140 million–$160 million from $160 million–$180 million as capital spending rises to $135 million, while the OSA PMA supplement submission was pushed to between the second half of 2026 and the first half of 2027.
LivaNova Trading Down 8.4%
NASDAQ:LIVN traded down $7.18 during midday trading on Wednesday, hitting $78.14. 1,862,507 shares of the company traded hands, compared to its average volume of 605,780. The firm’s fifty day moving average is $79.54 and its 200-day moving average is $70.61. LivaNova has a 12-month low of $45.64 and a 12-month high of $85.76. The firm has a market capitalization of $4.29 billion, a P/E ratio of 40.07 and a beta of 0.86. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24.
Key Headlines Impacting LivaNova
- Positive Sentiment: Quarterly results exceeded expectations: LivaNova reported second-quarter earnings of $1.26 per share, versus the $1.08–$1.09 analyst consensus, while revenue rose 10.8% year over year to $390.6 million, above the approximately $380.5 million estimate. LivaNova Q2 Earnings and Revenues Beat Estimates
- Positive Sentiment: 2026 earnings guidance was raised: The company now expects full-year adjusted EPS of $4.30 to $4.40, above the $4.15 consensus estimate. Revenue guidance was approximately $1.5 billion, broadly in line with expectations. LivaNova exceeds second-quarter forecasts and increases 2026 outlook
- Positive Sentiment: Analyst became more bullish: Needham raised its price target from $81 to $93 and assigned a Buy rating, implying meaningful potential upside from the referenced trading level. Benzinga
- Neutral Sentiment: Momentum has been strong: LivaNova recently reached a fresh 52-week high, but commentary noted that investors must weigh the company’s improving fundamentals against the possibility that additional gains are already reflected in the valuation. LivaNova Hits Fresh High
- Negative Sentiment: Shares pulled back despite the beats: The decline following the earnings release may reflect profit-taking after the recent rally, or investor concern that the roughly 40 times earnings valuation leaves limited room for further upside unless growth accelerates.
Analyst Ratings Changes
LIVN has been the subject of a number of research analyst reports. Needham & Company LLC raised their price objective on LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a research report on Wednesday. Robert W. Baird decreased their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research note on Thursday, May 7th. Barclays raised their price target on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Finally, Freedom Capital raised LivaNova to a “hold” rating in a research note on Tuesday, June 30th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $83.50.
Check Out Our Latest Analysis on LIVN
Insider Transactions at LivaNova
In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.35% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On LivaNova
Several institutional investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in LivaNova by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after purchasing an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock worth $32,012,000 after purchasing an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in LivaNova by 10.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after purchasing an additional 15,405 shares during the last quarter. Intech Investment Management LLC boosted its position in shares of LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after buying an additional 7,195 shares during the period. Finally, Strs Ohio purchased a new position in shares of LivaNova during the first quarter valued at approximately $130,000. Institutional investors own 97.64% of the company’s stock.
LivaNova Company Profile
LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.
The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.
Read More
- Five stocks we like better than LivaNova
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.
